Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · May 2014
Review Meta AnalysisThe association of indoor tanning and melanoma in adults: systematic review and meta-analysis.
Tanning beds are associated with increased risk of melanoma. ⋯ Using tanning beds is associated with a subsequent melanoma diagnosis. Exposure from more than 10 tanning sessions is most strongly associated and there was no statistically significant difference in this association before and after 2000, suggesting that newer tanning technology is not safer than older models.
-
J. Am. Acad. Dermatol. · May 2014
Review Meta AnalysisThe association of indoor tanning and melanoma in adults: systematic review and meta-analysis.
Tanning beds are associated with increased risk of melanoma. ⋯ Using tanning beds is associated with a subsequent melanoma diagnosis. Exposure from more than 10 tanning sessions is most strongly associated and there was no statistically significant difference in this association before and after 2000, suggesting that newer tanning technology is not safer than older models.
-
J. Am. Acad. Dermatol. · Mar 2014
ReviewSafety of dermatologic medications in pregnancy and lactation: Part II. Lactation.
Dermatologists are frequently faced with questions from women who are breastfeeding about the safety of commonly prescribed topical and systemic medications during lactation. Safety data in lactation, particularly regarding medications that are unique to dermatology, are limited and can be difficult to locate. We have consolidated the available safety data in a single reference guide for clinicians. We review literature pertaining to the safety of common dermatologic therapies in lactation and offer recommendations based on the available evidence.
-
J. Am. Acad. Dermatol. · Jan 2014
ReviewFrom the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Many studies have identified cardiovascular risk factors in patients with psoriasis. Some psoriasis therapies may increase cardiovascular disease (CVD) and others may decrease CVD. ⋯ Some therapies for moderate to severe psoriasis, including methotrexate and tumor necrosis factor inhibitors, may reduce cardiovascular events in psoriatic patients. Ustekinumab appears to be neutral but there may be a long-term benefit. Appropriate patient counseling and selection and clinical follow-up are necessary to maximize safety with these agents. Further long-term study is necessary to quantify the benefits and risks associated with biologic therapies.